Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716533 · ClinicalTrials.gov registry record · NA
Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)
A NA study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT01716533 is a NA study that has completed, run by GlaxoSmithKline. The registered enrollment target is 57 participants.
The verdict
NCT01716533, a NA study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study aims to 1) evaluate the C. difficile-specific immune response in CDI patients and 2) explore the difference in immune response between the patients with CDI recurrence and those with a sustained clinical response.
Interventions
- PROCEDURE Blood sampling
- OTHER Stool sample collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2013-02-02 |
| Est. Completion | 2015-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01716533
The ClinicalTrials.gov registry entry for NCT01716533 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood sampling is the first listed.
NCT01716533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01716533 about?
NCT01716533 is a clinical study titled "Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)". This study aims to 1) evaluate the C. difficile-specific immune response in CDI patients and 2) explore the difference in immune response between the patients with CDI recurrence and those with a sustained clinical response.
What is the current status of trial NCT01716533?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2013-02-02. Estimated completion is 2015-06-01.
What interventions are being tested in trial NCT01716533?
The interventions under investigation include: Blood sampling (PROCEDURE), Stool sample collection (OTHER).
Who is sponsoring clinical trial NCT01716533?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.